Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TXG 10x Genomics Inc
- Stocks
- Healthcare
- NASDAQ: TXG
Price (delayed)
$11.73
Market cap
$1.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.31
Enterprise value
$1.15B
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin
Highlights
The company's net income rose by 41% YoY and by 14% QoQ
TXG's EPS is up by 41% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of TXG
Market
Valuations
Earnings
Shares outstanding
123.13M
Market cap
$1.44B
Enterprise value
$1.15B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.84
Revenue
$624.66M
Gross profit
$427.01M
Operating income
-$172.39M
Net income
-$157.04M
EBIT
-$153.4M
EBITDA
-$111.37M
Free cash flow
$45.36M
Per share
Balance sheet
Liquidity
EPS
-$1.31
EPS diluted
-$1.31
Free cash flow per share
$0.37
Book value per share
$5.78
Revenue per share
$5.09
TBVPS
$7.21
Total assets
$903.39M
Total liabilities
$196.5M
Debt
$80.07M
Equity
$706.9M
Working capital
$471.83M
Debt to equity
0.11
Current ratio
5.37
Quick ratio
4.44
Net debt/EBITDA
2.67
Margins
Efficiency
Dividend
EBITDA margin
-17.8%
Gross margin
68.4%
Net margin
-25.1%
Operating margin
-27.6%
Return on assets
-17%
Return on equity
-21.9%
Return on invested capital
-30.9%
Return on capital employed
-19.3%
Return on sales
-24.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXG stock price
How has the 10x Genomics stock price performed over time
Intraday
0.26%
1 week
8.51%
1 month
36.55%
1 year
-40.91%
YTD
-18.31%
QTD
34.36%
Financial performance
How have 10x Genomics's revenue and profit performed over time
Revenue
$624.66M
Gross profit
$427.01M
Operating income
-$172.39M
Net income
-$157.04M
Gross margin
68.4%
Net margin
-25.1%
The company's net income rose by 41% YoY and by 14% QoQ
10x Genomics's net margin has increased by 41% YoY and by 16% QoQ
TXG's operating income is up by 37% year-on-year and by 11% since the previous quarter
10x Genomics's operating margin has increased by 37% YoY and by 13% QoQ
Price vs fundamentals
How does TXG's price correlate with its fundamentals
Growth
What is 10x Genomics's growth rate over time
Valuation
What is 10x Genomics stock price valuation
P/E
N/A
P/B
2.03
P/S
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.84
TXG's EPS is up by 41% year-on-year and by 14% since the previous quarter
The P/B is 82% below the 5-year quarterly average of 11.4 and 25% below the last 4 quarters average of 2.7
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 20.8 and 26% less than its last 4 quarters average of 3.1
10x Genomics's revenue has increased by 2.3% from the previous quarter
Efficiency
How efficient is 10x Genomics business performance
TXG's ROS is up by 40% year-on-year and by 15% since the previous quarter
The ROE has grown by 38% YoY and by 14% from the previous quarter
TXG's ROA is up by 38% YoY and by 14% from the previous quarter
The return on invested capital is up by 30% year-on-year and by 11% since the previous quarter
Dividends
What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXG.
Financial health
How did 10x Genomics financials performed over time
The company's quick ratio rose by 9% QoQ and by 4.2% YoY
The current ratio has grown by 8% from the previous quarter and by 2.9% YoY
10x Genomics's debt is 89% lower than its equity
10x Genomics's debt to equity has decreased by 15% YoY and by 8% QoQ
10x Genomics's debt has decreased by 13% YoY and by 3.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.